ReviewJournal of cardiovascular pharmacology2013
Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.
Review in Journal of cardiovascular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Bibliometric and visual analysis of miRNAs in heart diseases from 2004 to 2023.Frontiers in cardiovascular medicine · 2025Article
- Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches.Frontiers in nutrition · 2025Review
- Pathomechanisms and therapeutic opportunities in radiation-induced heart disease: from bench to bedside.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Review
- Dysregulated CD4+ T Cells and microRNAs in Myocarditis.Frontiers in immunology · 2020Review
- A myriad of roles of miR-25 in health and disease.Oncotarget · 2018Review
- Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases.Oxidative medicine and cellular longevity · 2018Review
- Deciphering Non-coding RNAs in Cardiovascular Health and Disease.Frontiers in cardiovascular medicine · 2018Review
- Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.Molecular therapy. Nucleic acids · 2017Review
- New insights into the immunopathogenesis of systemic lupus erythematosus.Nature reviews. Rheumatology · 2016Review
- Missing link between microRNA and prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.Oxidative medicine and cellular longevity · 2016Review
- Epigenetic associations in relation to cardiovascular prevention and therapeutics.Clinical epigenetics · 2016Review
- Micro-RNAs and macrophage diversity in atherosclerosis: new players, new challenges…new opportunities for therapeutic intervention?Biochemistry and biophysics reports · 2015Article
- Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity.Artificial DNA, PNA & XNA · 2014Review
- Expanding the therapeutic frontier in atherosclerosis.Journal of cardiovascular pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It is now appreciated that over 90% of the human genome is comprised of noncoding RNAs that have the ability to affect other components of the genome and regulate gene expression. This has galvanized the development of RNA-based therapeutics for a myriad of diseases, including cancer, inflammatory conditions, and cardiovascular disease. Several classes of RNA therapeutics are currently under clinical development, including antisense oligonucleotides, small interfering RNA, and microRNA mimetics and inhibitors. The field of antisense technology saw a huge leap forward with the recent Food and Drug Administration approval of the first antisense therapy, directed against apolipoprotein B, for the treatment of familial hypercholesterolemia. In addition, recent progress in the development of approaches to inhibit microRNAs has helped to illuminate their roles in repressing gene networks and also revealed their potential as therapeutic targets. In this review, these exciting opportunities in the field of drug discovery, with a focus on emerging therapeutics in the field of cardiovascular disease, are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.